Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma

Oncotarget

Volumn 6, Issue 38, 2015, Pages 40920-40933

  Zhang, Xiao Fei ^a   Chao, Jie ^b   Pan, Qiu Zhong ^a   Pan, Ke ^a   Weng, De Sheng ^a   Wang, Qi Jing ^a   Zhao, Jing Jing ^a   He, Jia ^a   Liu, Qing ^a   Jiang, Shan Shan ^a   Chen, Chang Long ^a   Zhang, Hong Xia ^a   Xia, Jian Chuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Shanxi Entry Exit Inspection and Quarantine Bureau   (China)

Author keywords

Hepatocellular carcinoma; Oncogene; Prognosis; WWP1

Indexed keywords

MESSENGER RNA; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING E3 UBIQUITIN PROTEIN LIGASE 1; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE; WWP1 PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; BEL 7402 CELL LINE; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CELL CYCLE ARREST; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; HEP 3B CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HUH7 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CELL CULTURE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SK HEP1 CELL LINE; SMMC 7721 CELL LINE; WESTERN BLOTTING; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; ENZYME IMMUNOASSAY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED; UBIQUITIN-PROTEIN LIGASES; YOUNG ADULT;

EID: 84951186412     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5712     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013; 63:11-30.
2. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013; 47:S2-6.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142:1264-1273 e1.
4. Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol. 2015; 7:1064-1073.
5. Lozano R, Naghavi M, Foreman K, Lim S, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2095-2128.
6. Cervello M1, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 2012; 3:236-260.
7. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012; 62:394-399.
8. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014:gutjnl. 2013; 306627.
9. A.X. Zhu, D.G. Duda, D.V. Sahani, R.K. Jain. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011; 292-301.
10. Wood JD, Yuan J, Margolis RL, Colomer V, Duan K, Kushi J, Kaminsky Z, Kleiderlein JJ, Sharp AH, Ross CA. Atrophin-1, the DRPLA gene product, interacts with two families of WW domain-containing proteins. Mol Cell Neurosci. 1998; 149-160.
11. Chen C, Matesic LE. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev. 2007; 587-604.
12. A. Hershko, A. Ciechanover. The ubiquitin system. Annu Rev Biochem. 1998; 67:425-479.
13. G. Melino. Discovery of the ubiquitin proteasome system and its involvement in apoptosis. Cell Death Differ. 2005; 1155-1157.
14. Mosser EA, Kasanov JD, Forsberg EC, Kay BK, Bresnick EH, Bresnick EH. Physical and Functional Interactions between the Transactivation Domain of the Hematopoietic Transcription Factor NF-E2 and WW Domains. Biochemistry. 1998; 37:13686-13695.
15. Joazeiro CA, Bowman ME, Wells NJ, Ferrer JL, Bowman ME, Hunter T, Noel JP. Conformational flexibility underlies ubiquitin ligation mediated by the WWP1 HECT domain E3 ligase. Mol Cell. 2003; 249-259.
16. Laine A, Ronai Z. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene. 2007; 26:1477-1483.
17. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69:1237-1245.
18. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003; 112:779-791.
19. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007; 128:141-156.
20. Wu W, Wang X, Zhang W, Reed W, Samet JM, Whang YE, et al. Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. J Biol Chem. 2003; 278:28258-28263.
21. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007; 128:129-139.
22. Chaudhary N, Maddika S. WWP2-WWP1 ubiquitin ligase complex coordinated by PPM1G maintains the balance between cellular p73 and δ Np73 levels. Mol Cell Biol. 2014; 34:3754-3764.
23. Li Y, Zhou Z, Chen C. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ. 2008; 1941-1951.
24. T. Ebisawa, M. Fukuchi, G. Murakami, T. Chiba, K. Tanaka, T. Imamura, K. Miyazono. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J Biol Chem. 2001; 276:12477-12480.
25. Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, Miyazono K, Miyazawa K. Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene. 2004; 23:6914-6923.
26. Lior H Katz, Ying Li, Jiun-Sheng Chen, Nina M Muñoz, Avijit Majumdar, Jian Chen, Lopa Mishra. Targeting TGF-β signaling in cancer. Expert Opin Ther Targets. 2013; 743-760.
27. Seo SR, Lallemand F, Ferrand N, Pessah M, L'Hoste S, Camonis J, et al. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO, J. 2004; 23:3780-3792.
28. Chen C, Zhou Z, Liu R, Li Y, Azmi PB, Seth AK. The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11. Oncogene. 2008; 27:6845-6855.
29. Li Y, Zhou Z, Alimandi M, Chen C. WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer. Oncogene. 2009; 28:2948-2958.
30. Chen C, Zhou Z, Ross J.S, Zhou W, Dong J.T. The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer. 2007; 121:80-87.
31. Ge F, Chen W, Qin J, Zhou Z, Liu R, Liu L, Tan J, Zou T, Li H, Ren G2, Chen C. Ataxin-3 like (ATXN3L), a member of the Josephin family of deubiquitinating enzymes, promotes breast cancer proliferation by deubiquitinating Krüppel-like factor 5 (KLF5). Oncotarget. 2015.
32. Chen C, Sun X, Guo P, Dong X.Y, Sethi P, Zhou W, et al. Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene. 2007; 26:2386-2394.
33. Lin JH, Hsieh SC, Chen JN, Tsai MH, Chang CC. WWP1 gene is a potential molecular target of human oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 116:221-231.
34. Dikic I, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014; 1242-1253.
35. Nguyen Huu NS, Ryder WD, Zeps N, Flasza M, Chiu M, Hanby AM, et al. Tumour-promoting activity of altered WWP1 expression in breast cancer and its utility as a prognostic indicator. J Pathol. 2008; 216:93-102.
36. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, et al. Gene expression profiles identify epithelial-tomesenchymal transition and activation of nuclear factorkappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006; 66:8210-8218.
37. Li Zhang, Zongyin Wu, Zhao Ma, Hongtao Liu, Yahong Wu, Qinxian Zhang. WWP1 as a potential tumor oncogene regulates PTEN-Akt signaling pathway in human gastric carcinoma. Tumor Biol. 2015; 36:787-798.
38. Peschiaroli A, Scialpi F, Bernassola F, El Sherbini el S, Melino G. The E3 ubiquitin ligase WWP1 regulates δ Np63-dependent transcription through Lys63 linkages. Biochem Biophys Res Commun. 2010; 402:425-430.
39. Xiaoxiao Cao, Lixiang Xue, Limin Han, Liwei Ma, Tianda Chen, Tanjun Tong. WW Domain-containing E3 Ubiquitin Protein Ligase 1 (WWP1) Delays Cellular Senescence by Promoting p27Kip1 Degradation in Human Diploid Fibroblasts. J Biol Chem. 2011; 286:33447-33456.
40. Li T, Fan J, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Tang ZY. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol. 2011; 1955-1963.
41. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004; 112:44-50.
42. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001; 570-575.
43. Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, Satomura S. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein < 20 ng/mL. Cancer Sci. 2011; 1025-1031.
44. Huang JY, Zhang K, Chen DQ, Chen J, Feng B, Song H, Chen Y, Zhu Z, Lu L, De W, Wang R, Chen LB. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma. Oncotarget. 2015; 6:18613-18630.